Apellis Pharmaceuticals, Inc.
Mid Cap · Healthcare · Biotechnology
$41.03+$0.00 (+0.00%)
Apellis Pharmaceuticals, Inc.
Mid Cap · Healthcare · Biotechnology
$41.03+$0.00 (+0.00%)
Stock analysis
Get the AI take on APLS
Track it to unlock the price chart, verdict and what could change it.
- ✓Live price chart
- ✓A clear accumulate, trim or avoid call
Free to track. No card required.
Stock Fundamentals & Key Indicators
52-week range
Low$16.61
High$41.14
Today $41.03
Overall score
71/100
See the full financial picture
Open the five-year record, valuation checks and Wall Street view behind these scores.
- ✓5 years of revenue, profit and cash flow
- ✓Valuation and balance-sheet checks
- ✓Business and geographic mix
- ✓Analyst targets and recommendation trend
Free for 3 days, then $9/mo. Cancel anytime.
Operating Record
Revenue
What's working
- ROIC: Money put back into the business keeps coming back out as profit, a hallmark of a durable moat.
- ROE: Shareholder capital is compounding at a rate worth paying attention to.
What to watch
- Debt exceeds cash by $69.6M, increasing balance-sheet pressure, a warning sign.
- Price / FCF: Cash generation hasn't caught up to the price tag yet.
What the market charges
Forward P/E
No signal · Not enough data to judge
-
Price / sales
Reasonable · Priced reasonably against its revenue
4.75x
Price / FCF
Rich · Priced far above what its cash flow currently supports
140.20x
EV / EBITDA
Rich · Operating earnings don't yet support this price
31.94x
How efficiently it compounds
ROIC
Strong · Comfortably clears the bar for efficient capital use
37.8%
ROE
Favorable · 46.0% - strong capital efficiency
46.0%
Debt / equity
Middle ground · Mixed
1.15x
Current ratio
Strong · Comfortable room to cover bills due within a year
3.63x
Peer Comparison
| Company | Mkt cap | P/E | Rev growth | Score |
|---|---|---|---|---|
| $5.25B | 38.3 | +42.5% | 71 |
 | $11.53B | 22.0 | +19.7% | 78 |
 | $4.60B | 13.9 | +13.5% | 77 |
 | $33.87B | 35.4 | +15.5% | 77 |
 | $1.11T | 40.1 | +49.6% | 76 |